Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $108,061.20 in Stock

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Kristen Yen sold 2,340 shares of the firm's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $46.18, for a total transaction of $108,061.20. Following the completion of the sale, the insider now directly owns 76,605 shares of the company's stock, valued at approximately $3,537,618.90. This represents a 2.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Soleno Therapeutics Trading Down 1.2 %

Soleno Therapeutics stock traded down $0.56 during mid-day trading on Monday, hitting $45.90. The company had a trading volume of 278,526 shares, compared to its average volume of 445,542. Soleno Therapeutics, Inc. has a 12 month low of $36.20 and a 12 month high of $60.92. The stock's 50 day moving average price is $51.24 and its two-hundred day moving average price is $49.24. The company has a market capitalization of $1.98 billion, a PE ratio of -13.83 and a beta of -1.47.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($1.22). Equities research analysts anticipate that Soleno Therapeutics, Inc. will post -3.7 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank purchased a new position in Soleno Therapeutics in the 2nd quarter worth approximately $31,000. Victory Capital Management Inc. increased its holdings in shares of Soleno Therapeutics by 26.3% in the 2nd quarter. Victory Capital Management Inc. now owns 10,727 shares of the company's stock worth $438,000 after purchasing an additional 2,236 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Soleno Therapeutics in the 3rd quarter worth $155,000. The Manufacturers Life Insurance Company raised its stake in shares of Soleno Therapeutics by 6.5% in the third quarter. The Manufacturers Life Insurance Company now owns 52,634 shares of the company's stock worth $2,657,000 after purchasing an additional 3,226 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Soleno Therapeutics by 35.8% during the third quarter. JPMorgan Chase & Co. now owns 13,915 shares of the company's stock valued at $703,000 after purchasing an additional 3,666 shares in the last quarter. Institutional investors own 97.42% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on SLNO shares. Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 price objective on shares of Soleno Therapeutics in a report on Friday, September 20th. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Stifel Nicolaus restated a "buy" rating and set a $74.00 price target on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Oppenheimer increased their price objective on Soleno Therapeutics from $65.00 to $73.00 and gave the stock an "outperform" rating in a report on Monday, October 28th. Finally, Robert W. Baird reissued an "outperform" rating and set a $72.00 price objective on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $74.83.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.